PDF(Pubmed)
Abstract：
Diabetic kidney disease (DKD) is one of the chronic microvascular complications caused by diabetes, which is characterized by persistent albuminuria and/or progressive decline of estimated glomerular filtration rate (eGFR), and has been the major cause of dialysis around the world. At present, although the treatments for DKD including lifestyle modification, glycemic control and even using of Sodium-glucose cotransporter 2 (SGLT2) inhibitors can relieve kidney damage caused to a certain extent, there is still a lack of effective treatment schemes that can prevent DKD progressing to ESRD. It is urgent to find new complementary and effective therapeutic agents. Growing animal researches have shown that mitophagy makes a great difference to the pathogenesis of DKD, therefore, exploration of new drugs that target the restoration of mitophagy maybe a potential perspective treatment for DKD. The use of Chinese botanical drugs (CBD) has been identified to be an effective treatment option for DKD. There is growing concern on the molecular mechanism of CBD for treatment of DKD by regulating mitophagy. In this review, we highlight the current findings regarding the function of mitophagy in the pathological damages and progression of DKD and summarize the contributions of CBD that ameliorate renal injuries in DKD by interfering with mitophagy, which will help us further explain the mechanism of CBD in treatment for DKD and explore potential therapeutic strategies for DKD.
摘要：
糖尿病肾病(DKD)是糖尿病引起的慢性微血管并发症之一。其特征是持续的蛋白尿和/或估计的肾小球滤过率（eGFR）的进行性下降，并且是全世界透析的主要原因。目前,虽然DKD的治疗包括改变生活方式，血糖控制，甚至使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂可以在一定程度上缓解肾脏损害。目前仍然缺乏有效的治疗方案来防止DKD进展为ESRD。迫切需要寻找新的补充和有效的治疗剂。越来越多的动物研究表明，线粒体自噬对DKD的发病机制有很大的影响，因此,探索靶向恢复线粒体自噬的新药可能是DKD的潜在治疗前景。已确定使用中国植物药（CBD）是DKD的有效治疗选择。人们越来越关注CBD通过调节线粒体自噬治疗DKD的分子机制。在这次审查中,我们强调了目前关于线粒体自噬在DKD病理损害和进展中的功能的发现，并总结了CBD通过干扰线粒体自噬改善DKD肾损伤的贡献，这将有助于我们进一步解释CBD治疗DKD的机制，并探索DKD的潜在治疗策略。
